Less than 5% of the data in the pharmaco-genomics database PharmGKB are from African populations. Only 15 out of over 300 drugs with FDA pharmacogenetic advice have been studied in African groups, highlighting the scarcity of pharmacogenomic research in these populations.
Pharmacogenetic data play a crucial role in selecting appropriate drugs for individuals and optimizing dosage. Specific gene mutations like HLA-B affecting antiviral drug responses or CYP2C9 altering blood thinner metabolism underscore the importance of personalized medicine.
[
add
]
[
|
|
...
]